Lipigon Pharmaceuticals AB is a Sweden-based project portfolio company. Lipigon's business concept is to develop medicines with new, unique mechanisms of action (so-called first-in-class) for diseases that lack adequate treatment. The Company develops medicines with a focus on diseases where the body's ability to handle fats is disturbed, so-called lipid-related diseases, and where there are unmet medical needs. Initially, the Company's development focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in the clinical development. It creates the conditions for studies with fewer patients and a shorter path to market approval and thus a reduced development risk.

• Revenue in SEK (TTM)9.33m
• Net income in SEK-20.25m
• Incorporated2010
• Employees--

• Location
  Lipigon Pharmaceuticals ABTvistevagen 48 CUMEA 907 36SwedenSWE
• Websitehttps://www.lipigon.se/